Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report

Abstract

Mucormycosis are a group of infections that affect principally immunocompromised host and have a high mortality. Liposomal amphotericin B is the first-line treatment with combined surgical removal of the infectious focus. We report the case of 67-year-old man with idiopathic granulocytic aplasia and a cutaneous lesion caused by Rhizopus arrhizus treated with isavuconazole. Its safety profile and spectrum of activity make it an important therapeutic option. Keywords: Mucormycosis, Cutaneous, Immunocompromised, Isavuconazole